Novel anticoagulants in atrial fibrillation

Monitoring, reversal and perioperative management

Fadi Shamoun, Hiba Obeid, Harish Ramakrishna

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Atrial fibrillation continues to be a significant source of morbidity and mortality worldwide. Effective anticoagulation remains the cornerstone of outpatient and inpatient treatment. The use of the new generation of anticoagulants (NOACs) continues to grow. Recently published data indicate their cost-effectiveness and overall safety in stroke prevention; compared to vitamin K antagonists, they can be prescribed in fixed doses for long-term therapy without the need for coagulation monitoring. Both United States and European Guidelines recommend NOACs for stroke prevention in patients with atrial fibrillation. This review discusses each of the NOACs, along with their efficacy and safety data. It explores the most recent guidelines regarding their perioperative use in atrial fibrillation patients. It also discusses bleeding complications, perioperative management, and reversal agents.

Original languageEnglish (US)
Article number424031
JournalBioMed Research International
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Anticoagulants
Atrial Fibrillation
Monitoring
Stroke
Guidelines
Safety
Vitamin K
Cost effectiveness
Coagulation
Cost-Benefit Analysis
Inpatients
Outpatients
Hemorrhage
Morbidity
Mortality
Therapeutics
N(4)-oleylcytosine arabinoside

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Novel anticoagulants in atrial fibrillation : Monitoring, reversal and perioperative management. / Shamoun, Fadi; Obeid, Hiba; Ramakrishna, Harish.

In: BioMed Research International, Vol. 2015, 424031, 2015.

Research output: Contribution to journalArticle

@article{fc8d422e79e54748a7248b766af231af,
title = "Novel anticoagulants in atrial fibrillation: Monitoring, reversal and perioperative management",
abstract = "Atrial fibrillation continues to be a significant source of morbidity and mortality worldwide. Effective anticoagulation remains the cornerstone of outpatient and inpatient treatment. The use of the new generation of anticoagulants (NOACs) continues to grow. Recently published data indicate their cost-effectiveness and overall safety in stroke prevention; compared to vitamin K antagonists, they can be prescribed in fixed doses for long-term therapy without the need for coagulation monitoring. Both United States and European Guidelines recommend NOACs for stroke prevention in patients with atrial fibrillation. This review discusses each of the NOACs, along with their efficacy and safety data. It explores the most recent guidelines regarding their perioperative use in atrial fibrillation patients. It also discusses bleeding complications, perioperative management, and reversal agents.",
author = "Fadi Shamoun and Hiba Obeid and Harish Ramakrishna",
year = "2015",
doi = "10.1155/2015/424031",
language = "English (US)",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Novel anticoagulants in atrial fibrillation

T2 - Monitoring, reversal and perioperative management

AU - Shamoun, Fadi

AU - Obeid, Hiba

AU - Ramakrishna, Harish

PY - 2015

Y1 - 2015

N2 - Atrial fibrillation continues to be a significant source of morbidity and mortality worldwide. Effective anticoagulation remains the cornerstone of outpatient and inpatient treatment. The use of the new generation of anticoagulants (NOACs) continues to grow. Recently published data indicate their cost-effectiveness and overall safety in stroke prevention; compared to vitamin K antagonists, they can be prescribed in fixed doses for long-term therapy without the need for coagulation monitoring. Both United States and European Guidelines recommend NOACs for stroke prevention in patients with atrial fibrillation. This review discusses each of the NOACs, along with their efficacy and safety data. It explores the most recent guidelines regarding their perioperative use in atrial fibrillation patients. It also discusses bleeding complications, perioperative management, and reversal agents.

AB - Atrial fibrillation continues to be a significant source of morbidity and mortality worldwide. Effective anticoagulation remains the cornerstone of outpatient and inpatient treatment. The use of the new generation of anticoagulants (NOACs) continues to grow. Recently published data indicate their cost-effectiveness and overall safety in stroke prevention; compared to vitamin K antagonists, they can be prescribed in fixed doses for long-term therapy without the need for coagulation monitoring. Both United States and European Guidelines recommend NOACs for stroke prevention in patients with atrial fibrillation. This review discusses each of the NOACs, along with their efficacy and safety data. It explores the most recent guidelines regarding their perioperative use in atrial fibrillation patients. It also discusses bleeding complications, perioperative management, and reversal agents.

UR - http://www.scopus.com/inward/record.url?scp=84937019528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937019528&partnerID=8YFLogxK

U2 - 10.1155/2015/424031

DO - 10.1155/2015/424031

M3 - Article

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 424031

ER -